Chronic wounds remain one of the most pressing and under-addressed health challenges worldwide, particularly for patients with diabetes, vascular disease, and trauma injuries. With more than $22 billion spent annually on wound care, most current treatments—ranging from wound vacs to grafts and antimicrobial creams—merely manage symptoms without tackling the root cause. The result is persistent tissue damage, infections, and, for many, eventual amputation.
California-based med-tech company Rapid Nexus has developed a groundbreaking device that goes beyond symptom management. Its patented technology regenerates nerve-damaged tissue and restores circulation, effectively reversing chronic wounds and offering new hope for millions at risk of limb loss.
Early results are remarkable. In a 2018 feasibility study, every patient slated for amputation avoided the procedure after treatment with Rapid Nexus’s device. One young mother, facing the loss of her leg due to necrosis, regained mobility and independence once her blood flow and nerves were restored.
Unlike conventional antimicrobial approaches, Rapid Nexus’s solution heals without damaging surrounding healthy tissue. Peer-reviewed research to be published this fall shows unprecedented results, with dozens of biomarkers confirming nerve and vascular regeneration.
Founded by dentist and inventor Dr. Margaret Kalmeta, the technology evolved from regenerative methods in dentistry and has since expanded into full-body applications. “This is about restoring human dignity, one limb at a time,” Kalmeta explains.
The device is now in final FDA review, with clinical trials underway at leading U.S. hospitals and ongoing discussions with the Department of Veterans Affairs and military medical teams. Backed by $3.8 million in seed funding and winner of a TechConnect Defense Innovation Award, Rapid Nexus plans commercial rollout by late 2025, targeting hospitals, home care, and underserved communities globally.
Artículo escrito por el equipo de redacción de infomednews
06/10/2025
Source:
Infomed news